Metastatic castration-resistant prostate cancer – New learnings and perspectives

Prof. de Wit (NL) gave a summary of the CARD study: a randomized, open-label study of cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer.